Protocols
ADICET-ADI-001-LTFU Phase N/A OPEN TO ACCRUAL
Long-term Follow-up Protocol for Subjects Treated with Adicet Bio Allogeneic Gamma Delta T Cell Investigational Products
ALEXION-ALXN1210-TMA-313 Phase III OPEN TO ACCRUAL
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
ALLOVIR-P-106-001-RESP Phase I/II OPEN TO ACCRUAL *
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
CIBMTR-10-CBA Phase N/A OPEN TO ACCRUAL
A Multicenter Access And Distribution Protocol For Unlicensed Cryopreserved Cord Blood Units (CBUs) For Transplantation In Pediatric And Adult Patients With Hematologic Malignancies And Other Indications
CTN-1705 Phase III OPEN TO ACCRUAL
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host-Disease (GVHD) Following Hematopoietic Stem Cell Transplant
HJKC3-0002 Phase II OPEN TO ACCRUAL *
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
HJKC3-0003 Phase II OPEN TO ACCRUAL *
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
IIT-ATALLAH-CLAGM-AML Phase II OPEN TO ACCRUAL
A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML)
IIT-SHAH-TRIPLE-CAR20-19-22 Phase I OPEN TO ACCRUAL
Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
KARTOS-KRT-232-101-MF Phase II OPEN TO ACCRUAL *
An Open-label, Phase 2a/2b Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), or Post Essential Thrombocythemia MF (Post ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor